Antimicrobial offers improved safety and tolerability

July 26, 2004

Trichomoniasis is a sexually transmitted disease with potentially serious sequelae. Fortunately, clinicians will soon be able to offer patients with this condition a new molecular entity. The FDA recently approved tinidazole (Tindamax, Presutti Laboratories) for the treatment of trichomoniasis caused by Trichomonas vaginalis in both female and male patients; giardiasis caused by Giardia duodenalis (also called G. lamblia) in both adults and pediatric patients older than three years of age; and amebiasis and amebic liver abscess caused by Entamoeba histolytica in adults and children older than three years of age. Tinidazole will be available in pharmacies sometime this month